Currencies / ABBV
ABBV: AbbVie Inc
190.48
USD
2.07
(1.10%)
ABBV exchange rate has changed by 1.10% for today. During the day, the instrument was traded at a low of 188.32 and at a high of 191.09.
Follow AbbVie Inc dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ABBV News
- Investing Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade
- Investing HSBC upgrades Divi’s Laboratories stock rating to Buy on growth potential
- Investing Prime Medicine stock soars amid gene editing sector momentum
- Yahoo Finance Here's What to Expect From AbbVie's Next Earnings Report
- Seeking Alpha 2 ETFs To Prepare You For A Potential Recession
- The Motley Fool 3 No-Brainer Stocks to Buy in July
- Seeking Alpha IGA: Strong Performance From Foreign Exposure And Fully-Covered Distribution
- The Motley Fool 2 Dividend Stocks to Buy for Decades of Passive Income
- Seeking Alpha NYLI Income Builder Fund Q1 2025 Commentary
- The Motley Fool Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
- Seeking Alpha AbbVie: Q2 Earnings Warning Reflects Poor R&D, But It's Not A Red Flag (NYSE:ABBV)
- TipRanks AbbVie’s (ABBV) Forecasts Lower Q2 EPS on R&D Costs - TipRanks.com
- Seeking Alpha NYLI Epoch Global Equity Yield Fund Q1 2025 Commentary
- Benzinga Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial - Novartis (NYSE:NVS)
- Seeking Alpha Aldeyra Stock: Pivotal FDA Decision After Reproxalap’s Chamber Data (NASDAQ:ALDX)
- Seeking Alpha THQ: Valuation Remains Unappealing Even If Portfolio Is Beaten-Down (NYSE:THQ)
- Seeking Alpha LENZ Therapeutics: Presbyopia Eyedrops Look Promising (NASDAQ:LENZ)
- Seeking Alpha Dividend Yield Theory Says Merck Is A Buy (NYSE:MRK)
- Seeking Alpha 2025 H1 Portfolio Review: More Ways To Win
- TipRanks AbbVie Stock (ABBV) Jumps on $2.1B Capstan Therapeutics Deal - TipRanks.com
- Investing Morgan Stanley reiterates Overweight rating on AbbVie stock at $250
- Investing Palantir, Circle Internet Surge Among Monday’s Market Cap Stock Movers
- Investing AbbVie to Host Second-Quarter 2025 Earnings Conference Call
- Reuters AbbVie to buy Capstan Therapeutics for up to $2.1 billion
Daily Range
188.32
191.09
Year Range
163.81
218.67
- Previous Close
- 189.91
- Open
- 188.41
- Bid
- 190.48
- Ask
- 190.78
- Low
- 188.32
- High
- 191.09
- Volume
- 7.981 K
- Daily Change
- 1.10%
- Month Change
- 2.86%
- 6 Months Change
- 3.99%
- Year Change
- 1.44%
10 July, Thursday
12:30
USD
- Act
- Fcst
- 228 K
- Prev
- 233 K
12:30
USD
- Act
- Fcst
- 1.998 M
- Prev
- 1.964 M
12:30
USD
- Act
- Fcst
- 237.294 K
- Prev
- 241.500 K
14:30
USD
- Act
- Fcst
- 76 B
- Prev
- 55 B
15:30
USD
- Act
- Fcst
- Prev
- 4.240%
15:30
USD
- Act
- Fcst
- Prev
- 4.300%
17:00
USD
- Act
- Fcst
- Prev
- 4.844%
17:15
USD
- Act
- Fcst
- Prev